AUTHORS
Rima M. Saliba, PhD, Gabriela Rondon, MD2, Gheath Alatrash, PhD3, Yosra M. Aljawai, MD MS4, Amin Alousi, MD5, Qaiser Bashir, MD6, George Chen, MD7, Warren Fingrut, MD, MPH8, Chitra Hosing, MD9, Partow Kebriaei, MD10, David Marin11, William Matsui, MD12, Rohtesh Mehta, MD, MPH13, Yago Nieto, MD, Ph.D14, Betul Oran, MD15, Muzaffar Qazilbash, MD16, Jeremy Ramdial, MD17, Neeraj Saini, MD18, Terri Lynn Shigle19, Portia Smallbone, MBBS (Hons), FRACP, FRCPA20, Samer A Srour, MB ChB, MS21, Richard Champlin22, Elizabeth Shpall, MD23, Uday Popat, MD, MBA24
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, United States
2 The University of Texas MD Anderson Cancer Center, Houston, United States
3 The University of Texas MD Anderson Cancer Center, Houston, United States
4 The University of Texas MD Anderson Cancer Center, Houston, United States
5 The University of Texas MD Anderson Cancer Center, Houston, United States
6 The University of Texas MD Anderson Cancer Center, Houston, United States
7 The University of Texas MD Anderson Cancer Center, Houston, United States
8 The University of Texas MD Anderson Cancer Center, Houston, United States
9 The University of Texas MD Anderson Cancer Center, Houston, United States
10 The University of Texas MD Anderson Cancer Center, Houston, United States
11 The University of Texas MD Anderson Cancer Center, Houston, United States
12 The University of Texas MD Anderson Cancer Center, Houston, United States
13 The University of Texas MD Anderson Cancer Center, Houston, United States
14 The University of Texas MD Anderson Cancer Center, Houston, United States
15 The University of Texas MD Anderson Cancer Center, Houston, United States
16 The University of Texas MD Anderson Cancer Center, Houston, United States
17 The University of Texas MD Anderson Cancer Center, Houston, United States
18 The University of Texas MD Anderson Cancer Center, Houston, United States
19 The University of Texas MD Anderson Cancer Center, Houston, United States
20 The University of Texas MD Anderson Cancer Center, Houston, United States
21 The University of Texas MD Anderson Cancer Center, Houston, United States
22 The University of Texas MD Anderson Cancer Center, Houston, United States
23 The University of Texas MD Anderson Cancer Center, Houston, United States
24 The University of Texas MD Anderson Cancer Center, Houston, United States
ABSTRACT
Background
The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) is a widely used tool for prediction of non-relapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) for treatment of hematologic malignancies. This risk-stratification system was developed before the widespread use of post-transplant cyclophosphamide (PTCy)-based GvHD prophylaxis which significantly reduced the incidence of severe acute and chronic GvHD and associated mortality and morbidity. The utility of HCT-CI and its performance in contemporary HCT cohorts with PTCy-based GvHD prophylaxis is not well characterized. The objective of this study was to evaluate the prognostic significance of each HCT-CI comorbidity and identify the subset that predicts NRM in patients receiving PTCy-based GvHD prophylaxis.
Methods
We retrospectively analyzed consecutive adults undergoing first allogeneic peripheral blood or bone marrow HCT between 2018 and 2024 who received PTCy-based GvHD prophylaxis at our institution. The primary endpoint was 1-year NRM. All 15 HCT-CI comorbidities were evaluated. Comorbidities with a prevalence of <5% -renal disease (<1%), inflammatory bowel disease (1%), peptic ulcer disease (1%), heart valve disease (2%), cerebrovascular disease (4%), and rheumatologic disease (4%)- were excluded from risk factors analysis. A simplified PTCy-specific comorbidity index was developed based on the magnitude and statistical significance (defined at .05 level) of the association between each individual comorbidity and NRM. NRM rate was estimated and compared accounting for competing risks.
Results
A total of 1,836 patients were included. Median age was 60 years (range, 18–81), and median HCT-CI score was 3 (range, 0–10). 77% had White race and 14% Hispanic ethnicity. AML/MDS was the most common indication for transplantation (68%), followed by CML/MPN (13%) and ALL (7%). Disease Risk Index (DRI) was intermediate (61%), high ( 27%), or very high (4%). Conditioning regimens were myeloablative (78%) or reduced intensity (22%). GvHD prophylaxis consisted of PTCy/tacrolimus with (82%) or without (18%) mycophenolate mofetil. Peripheral blood was the predominant graft source (80%), while 20% received bone marrow grafts. Donors were HLA-matched unrelated (47%), -matched related (24%), haploidentical (20%), or -mismatched unrelated (9%). Median follow-up among survivors was 37 (range 3-94) months. The cumulative incidence of NRM was 17% (95% CI 15-18) at 1-year and 19% (95% CI 17-21) at 3-years. In univariable analysis, cardiac disease (HR 2.5, P<0.001) and severe pulmonary disease (HR 2.4, P<0.001) were the strongest predictors of NRM. Additional significant predictors included infection (HR 1.7, P=0.002), arrhythmia (HR 1.6, P=0.006), moderate pulmonary disease (HR 1.5, P=0.003), diabetes (HR 1.5, P=0.01), obesity (HR 1.4, P=0.04), and psychiatric disease (HR 1.3, P=0.02). Hepatic disease (HR 1.2, P=0.1) and prior solid tumors (HR 1.2, P=0.1) were not associated with NRM. Based on these findings, we developed PTCy Comorbidity Index (PTCy-CI) as the sum of the significant comorbidities assigning two points each for cardiac and severe pulmonary disease and one point each for arrhythmia, diabetes, infection, moderate pulmonary disease, obesity, and psychiatric disease. The total PTCy-CI score distribution was 0 (30%), 1 (32%), 2 (21%), 3 (10%), and ≥4 (7%), corresponding to 1-year NRM of 10%, 15%, 18%, 20%, and 44%, respectively. The respective 3-year NRM was 12%, 18%,19%, 23%, and 46%. In multivariable analysis (MVA), PTCy-CI scores of 1 (HR 1.7, 95% CI 1.2–2.5; P=0.001), 2-3 (HR 2.1, 95% CI 1.5–2.9; P<0.001), and ≥4 (HR 5.8, 95% CI 4.0–8.5; P<0.001) were associated with progressively higher NRM compared with a score of 0. Notably, PTCy-CI was not associated with recipient age (P=0.1) or DRI (P=0.1) and these two factors remained independent significant predictors of NMA in MVA. Internal validation using bootstrapping was consistent with these findings. Substituting PTCy-CI for the traditional HCT-CI improved the discrimination of 1-year NRM rate based on Harrell’s C criteria.
Conclusion
A simplified PTCy-specific comorbidity index (PTCy-CI) provided superior prediction of NRM compared with the traditional HCT-CI in the contemporary era of PTCy-based GVHD prophylaxis. If externally validated, the PTCy-CI may serve as a more accurate and clinically relevant tool for pre-transplant risk stratification.
DISCLOSURES
Rima M. Saliba, PhD: No relevant conflicts of interest to declare.